Pyoderma Gangrenosum (Dɔléle ƒe Mɔ̃): Violaceous Submined Ulcer si Keke Ðe Edzi Kabakaba Kple Nusita Amekoko ƒe Debridement Gblẽa Necrosis Gblẽa Nu Vɔ̃ɖitɔe¶

Pyoderma gangrenosum (PG) nye neutrophilic dermatosis si mebɔ o, si mexɔa dɔlékui o, si xɔa dɔléle si nye autoinflammatory neutrophilic dermatosis si me dzɔdzɔmeŋusẽ ƒe dɔlélenutsiŋutete ƒe dzesi siwo ŋu womewɔa ɖoɖo nyuie o ʋãa polymorphonuclear neutrophils tsitsi siwo me dɔlékui mele o gbogbo aɖewo yia ŋutigbalẽa me, eye wònaa collagen kple ŋutigbalẽ te lãkusiwo ƒuna le gaƒoƒo va ɖo ŋkekewo me. Togbɔ be woto eƒe ŋutinya me ŋkɔ si flua ame vɛ le ƒe 1930 me hã la, pyoderma gangrenosum menye menye dɔlékui ƒe dɔléle ("pyoderma") alo ischemic vascular gangrene vavãtɔ o. Ke boŋ zi geɖe la, edzea egɔme abe abi si me dɔlékui mele o, ʋuʋudedi si me dɔlékui mele o, alo ʋuka si me ʋu sina tona le ŋutigbalẽ me, si dzea egɔme zi geɖe le afisi tututu ŋutigbalẽ ƒe abi sue aɖe, nudzodzoewo ƒe ɖuɖu, ʋuka si woɖe, alo amekoko ƒe lãɖeɖe, si nye nudzɔdzɔ ɖedzesi aɖe si woyɔna be lãgbalẽ ƒe dɔléle (si le dɔnɔ 30 va ɖo 50 le alafa me me). Le gaƒoƒo 24 va ɖo 72 me la, ʋuʋudedi si me dɔlékui mele o la gbãna le titina eye wòkekena ɖe enu le titina le duƒuƒu dziŋɔ aɖe me (sentimeta 1 va ɖo 2 gbesiagbe) zua do si me vevesese le ŋutɔ, si me ʋuʋudedi le, si me ʋuʋudedi le si ŋu dɔlékui boggy, gunmetal-gray to deep violaceous (purple-blue), undermined, overhanging ƒo xlãe liƒo si ŋu erythematous halo si le keklẽm ƒo xlãe. Dɔnɔ siwo ŋu pyoderma gangrenosum le dometɔ 50 va ɖo 70 le alafa me ƒe ɖoɖowɔɖi ƒe dɔléle aɖe le wo ŋu, eye zi geɖe la, Dɔléle si naa dɔgbo ƒe dɔléle (Ulcerative Colitis alo Crohn Disease), Rheumatoid Arthritis alo Seronegative Spondyloarthritis, Monoclonal Gammopathy (vevietɔ IgA paraproteinemia), alo Ʋudɔléle vɔ̃ɖi (Acute Myeloid Leukemia alo Myelodysplastic Syndrome). Elabena abi si kekena kabakaba, si me ʋuʋudedi le, si kpe ɖe asrã, vevesese sesẽ, kple ʋumenugbagbevi ɣi siwo ƒe xexlẽme nye lãmenugbagbevi 20,000 va ɖo 40,000/mcL ŋu la srɔ̃a necrotizing fasciitis (dɔlékui si ɖua ŋutilã) alo abi ƒe ʋuʋu le dɔwɔwɔ vɔ megbe, amekola siwo menya pyoderma o gangrenosum nana dɔnɔa ƒua du yia amekokoxɔa me enuenu be woaɖee le amekoko me le mɔ gbadza nu. Le pyoderma gangrenosum me la, amekola ƒe scalpel ƒe ƒoƒo ɖesiaɖe hea pathergic neutrophil ahom si wóna vɛ le ŋutigbalẽ ƒe axa si wotso yeyee, si wɔnɛ be abi la ƒe lolome dzina ɖe edzi zi gbɔ zi eve alo etɔ̃ le zã ɖeka me, si wɔnɛ be lãkusiwo kple ƒuwo dzena, alo wònana wolãa abɔ kple afɔ madzemadzee. Ne abi si le ta kekem kabakaba si ƒe liƒo si ƒe amadede nye aŋutiɖiɖi si gblẽ le dɔnɔ aɖe ŋu le nuveviwɔame suesuesue alo amekoko megbe la, ƒo ka na miaƒe nutoa me tɔwo xexlẽdzesi siwo wozãna kpata alo nàdi kɔdzi ƒe ŋutigbalẽŋutinunya ƒe dodokpɔ kpata enumake. Dzro mía nɔviwo ŋuti mɔfiamegbalẽ siwo ku ɖe... calciphylaxis, violaceous retiform kpeƒekpeƒewo, kple sodium thiosulfate, . erysipelas vs necrotizing fasciitis vs stasis ŋutigbalẽ ƒe dɔléle ƒe vovototodedeameme, kple ahosi ameyibɔ latrodectism vs brown recluse loxoscelism ameyibɔ ƒe abi triage.

Nusiwo nàtsɔ aɖo nɔƒe gbãtɔ le nudzɔdzɔ kpatawo me enumake enye be tsɔ nuxlɔ̃ame si nye "MÈGAKƆ AMEKO ME O" da ɖe dɔnɔa ƒe nɔnɔmetata kple abitutu dzi enumake, ade vovototo pyoderma gangrenosum kple necrotizing soft-tissue infection vavãtɔ dome to abadzivɔ ƒe dɔdamɔnu dodokpɔ, Gram stain, lãmenugbagbeviwo ƒe dekɔnuwo, kple PARACELSUS alo Delphi Diagnostic si ŋu woda asi ɖo la zazã me Dzesidenuwo, wɔ ŋuɖɔɖɔɖo ƒe elliptical alo punch skin biopsy le active violaceous border (ne ehiã ko be woaɖe dɔlékui, vasculitis, alo malignancy ɖa, eye le nɔnɔme nyuitɔ me esime wole systemic immunosuppression gɔme dzem be blunt biopsy pathergy), eye adze rapid-acting systemic anti-neutrophil immunosuppression gɔme, vevietɔ high-dose systemic Corticosteroids (Prednisone 1 va ɖo 2 mg/kg/ŋkeke alo pulse IV Methylprednisolone 500 va ɖo 1,000 mg/ŋkeke hena ŋkeke 3), Cyclosporine si woano (4 va ɖo 5 mg/kg/ŋkeke), alo Infliximab si wodona ɖe ʋuka me (5 mg/kg, si nye sika dzidzenu na Crohn/Ulcerative Colitis-associated kple peristomal PG) ƒe dɔwɔwɔ.

Wɔ esia fifia¶

1. Di Kɔdzi Kpata Kple Lãmesẽnyawo Ŋuti Numekuku Kpata ne ŋutigbalẽ ƒe ʋuʋudedi, amekoko ƒe lãɖeɖe, alo abi sue aɖe ƒo kabakaba va zu do si me vevesese sesẽ aɖe le si ƒe liƒo nye aŋutiɖiɖi-blɔ, tsikpe, si le tsia dzi. Ƒo ka na 911 le United States kple Canada, 999 le United Kingdom, 112 le Europa Dukɔwo ƒe Habɔbɔ bliboa me, 000 le Australia, alo kpɔ míaƒe xexeame katã ƒe nyatakakadzraɖoƒe si nye xexlẽdzesi siwo wozãna kpata.
2. DZUDZƆ Amekoko Siwo Ŋu Wowɔ Ðoɖo Ðo Ðe No Ƒe Ʋuʋu alo Eɖeɖe Kpuie Ŋu Enumake (The Pathergy Trap): Ne dɔnɔ aɖe nya alo susui vevie be pyoderma gangrenosum (si me Postoperative Pyoderma Gangrenosum [PPG] si dzena le ŋkeke 4 va ɖo 14 le no dzi ɖeɖe kpɔtɔ/gbugbɔgatu vɔ megbe hã le, la, woɖee le no me, dzitodzito me dɔléle amekoko, alo ƒodo me stoma wɔwɔ), wotsi tre ɖe amekoko ɖaɖɛ ƒe lãɖeɖe kple scalpel alo curette ŋu vevie. Amekoko ƒe lãɖeɖe xɔa ʋumenugbagbevi dzĩ siwo IL-1beta-, IL-8-, kple TNF-alpha ʋãna ƒe ƒutsotsoe gãwo yia ŋutigbalẽ si wotso yeyee la me, si wɔnɛ be abi si gblẽa nu le ame ŋu si woyɔna be centrifugal ulceration le akɔta, ƒodo, alo abɔ kple afɔ bliboa me le gaƒoƒo 24 me.
3. Ðe Necrotizing Fasciitis, Ecthyma Gangrenosum, Kple Deep Fungal Infection Nyateƒetɔ ɖa Evɔ Màhe Radical Excision Si Mehiã O Gbɔ O:
4. Nusita Woble Amekolawo: Pyoderma gangrenosum hea ʋuʋudedi ɣi si me dɔlékui mele o si le abe kreme ene (si me neutrophil kuku miliɔn geɖe le), dzoxɔxɔ sesẽ, kple ʋumenugbagbeviɣidɔ si ade 35,000/mcL vɛ.
5. Alesi Woaɖe Wo Vovo le Abati Gbɔ: To vovo na necrotizing fasciitis (si kakana ɖe lãkusi te ƒe fascia do ŋgɔ le ŋutigbalẽ ƒe gbagbã si wokpɔna me, ewɔa subcutaneous gas/crepitus, "distsiter" tsi ƒoɖi, kple systemic septic shock kple hypotension kple lactic acidosis), pyoderma gangrenosum nye gbãtɔ ŋutigbalẽ ƒe abi si ƒe liƒo sesẽ, si me agado le, si me tu-violaceous gblẽ le overhang, zero subcutaneous gas, zero foul anaerobic odor, palpable peripheral pulses, kple negative Gram stains and blood cultures.
6. PG ƒe Kpeɖodzinya: Dɔlékui siwo wua abi ƒe dɔlékui siwo dona le dɔwɔwɔ vɔ megbe la dzea ame dzi zi geɖe le gaƒoƒo 24 va ɖo 72 me le amekokoa megbe (Ƒuƒoƒo A Streptococcus alo Clostridium) alo wodzena abe stitch abscess si nɔa tɔtrɔm ene, gake Postoperative Pyoderma Gangrenosum (PPG) ya dona tso 4 va ɖo Ŋkeke 14 le dɔwɔwɔ vɔ megbe abe ʋuʋudedi sue geɖe siwo me dɔlékui mele o le suture line la dzi siwo ƒoa ƒu heɖea lãɖeɖe bliboa ɖa esime ɖea no ƒe areola si ƒe amadede le ɣie la ɖa le no ƒe dɔwɔwɔ me eye womete ŋu nyona ɖe edzi le broad-spectrum IV dɔlékuiwutikewo me o.
7. Zã Dɔlélewo Ŋuti Dɔwɔɖoɖo Siwo Ŋu Woda Asi Ðo (Delphi Dukɔwo Dome Nusɔsrɔ̃ ƒe Dzesidewo kple PARACELSUS ƒe Dzeside) eye Nàxɔ Liƒodzidɔdamɔnu si Woɖo Tae:
8. Le 2018 Delphi Dukɔwo Dome Nubabla te la, dɔléle didi bia 1 Major Criterion (biopsy of the ulcer edge ɖee fia be dense sterile neutrophilic dermal infiltrate) kpe ɖe 4 ya teti le 8 me Dzeside Sue (woɖe dɔlékui si woxɔ le histology/culture; pathergy; IBD alo inflammatory arthritis ŋutinya; papule/pustule ulcerating le ŋkeke 4 me, peripheral erythema, kple vevesese geɖe si me ɖeka ya teti le le afɔ si le ete ŋu cribriform alo "crushed tissue paper" abi siwo le ʋuʋum le teƒe siwo woda gbe le;
9. Le PARACELSUS Dzeside (afisi dzesi si nye >= dzesi 10 fia be PG ƒe kakaɖedzi > 90%) te la, wonaa dzesi veviwo na Pdɔléle si le ŋgɔ yim (3 pts), Avovototodedeameme siwo sɔ ƒe dodokpɔ (3 pts), kple Reddish-violaceous abi ƒe liƒo (3 pts), kpakple Amelioration by immunosuppressants (2 pts), **C ** nɔnɔme si nye abi ƒe nɔnɔme wɔnuku (2 pts), Eveve sesẽ > 4/10 le VAS (2 pts), kple Localized pathergy phenomenon (2 pts).
10. Dze Systemic Corticosteroids alo Cyclosporine ƒe agbɔsɔsɔ gã zazã gɔme enumake be nàtɔ te Neutrophil ahom la:
11. First-Line Systemic Rescue (STOP GAP Trial Evidence): Na Prednisolone/Prednisone si woano le 0.75 va ɖo 1.5 mg/kg/ŋkeke (vaseɖe 60 va ɖo 100 mg/ŋkeke), alo na fulminant, si kekena kabakaba multilocular alo le dɔwɔwɔ vɔ megbe PG la, na Pulse Intravenous Methylprednisolone (500 va ɖo 1,000 mg IV zi ɖeka gbesiagbe hena ŋkeke 3 va ɖo 5 tsiã ɖe enu), si zi geɖe léa centrifugal border expansion eye wòɖea vevesese sesẽ dzi kpɔtɔna le gaƒoƒo 48 va ɖo 72 me.
12. Alternative First-Line Rescue (Oral Cyclosporine): UK ƒe dzesi ɖedzesi STOP GAP randomized controlled trial ɖo kpe edzi be Oral Cyclosporine le 4 va ɖo 5 mg/kg/ŋkeke (si woma zi eve gbesiagbe) ƒe abidada ƒe dɔwɔwɔ kple duƒuƒu sɔ kple prednisolone si woano, si wɔe be Cyclosporine nye atike gbãtɔ si wodi wu le dɔnɔwo me kple suklidɔ si mebɔ o, ƒumeŋuɖui sesẽ, lolo akpa, alo steroid ƒe susu ƒe dɔmawɔmawɔ nyuie (ƒo asa na Cyclosporine le ayiku ƒe dɔmawɔmawɔ nyuie alo ʋusɔgbɔdɔ si dzi womeɖu o me).
13. Dze Biologic TNF-Alpha Blockade (IV Infliximab 5 mg/kg) gɔme na Inflammatory Bowel Disease-Ssociated, Peristomal, alo Steroid-Refractory Pyoderma Gangrenosum: Infliximab si wodona ɖe ʋuka me (5 mg/kg le Kwasiɖa 0, 2, kple 6 me, emegbe kwasiɖa 8 ɖesiaɖe) koe nye nugbagbeŋutinunya ƒe atikewɔwɔ si do alɔe to dodokpɔ si wowɔ le vome si me wozã atike si wotsɔ ɖɔa amee le hena pyoderma gangrenosum, si na wokpɔ dɔdamɔnu ƒe ŋuɖoɖo kabakaba le dɔnɔ 69 le alafa me le kwasiɖa 2 me eye wònye atike si ŋu womeʋlia nya le o si wotia ne PG nɔa anyi ɖekae kple Crohn dɔléle si le dɔ wɔm, Ulcerative Colitis, alo peristomal ulceration.
14. Strictly Atraumatic, Moisture-Balanced Local Wound Care and Gentle Compression: Mègatsɔ gaze ƒuƒu si léna ɖe abi ƒe aba ŋu eye wòvuvua ŋutigbalẽ si ate ŋu anɔ agbe ne woɖee ɖa gbeɖe o (si hea pathergy vɛ). Takpɔ ŋutigbalẽ si ƒo xlãe si me gblẽ o kple zinc oxide alo cyanoacrylate mɔxenu film, de ami si nye clobetasol propionate 0.05% si ŋu ŋusẽ le ŋutɔ alo tacrolimus 0.1% ami si wotsɔna ƒoa ɖa ɖe liƒo si le dziƒo si xɔ dzo la dzi, tsɔ silicone mesh, hydrogel, alo hydrofiber/alginate dressings, eye nàde gentle multi-layer compression bandaging ne wonya ɖu liƒo ƒe vevesese sesẽ dzi to systemic steroids dzi ko.

Nyametsotsoti: wosusu be Pyoderma Gangrenosum kple Necrotizing Fasciitis vs Venous/Arterial Ulcer vs Martorell Ulcer¶

flowchart TD
    A["Dɔnɔa tsɔa ŋutigbalẽ ƒe abi si kekena kabakaba, si vea ame vevie (sentimeta 1 va ɖo 2/ŋkeke) + Purulent Yellow Base + Boggy Violaceous/Gunmetal-Gray Undermined Overhanging Border (Zi geɖe Le Nuveviwɔame Suewo, Venipuncture, alo Amekoko Nyitsɔ laa megbe)"] --> B{"Afɔɖeɖe 1: Ðe Womaɖe Lãmetsi Falɛfalɛwo ƒe Dɔlékui Nyateƒetɔ (Necrotizing Fasciitis) ɖa Enumake: Ðe Ya/Crepitus, Ʋeʋẽ vɔ̃ si me ya mele o, Fascial Tracking Beyond Skin Margins, alo Septic Shock Lia?"}
    B -->|YES: True Bacterial Necrotizing Fasciitis / Wet Gangrene| C["Amekoko Kpata ƒe Dɔwɔƒe Amekoko ƒe Kukuɖenuŋu & Ðeɖekpɔkpɔ + IV Vancomycin + Piperacillin-Tazobactam/Meropenem + Clindamycin"]
    B -->|NO: Primary Dermal Ulceration with Violaceous Undermined Overhang + Negative Gram Stain + Palpable Pulses| D["Afɔɖeɖe 2: Zã PARACELSUS Dzeside (>= 10 Points) & Screen na Systemic Habɔbɔwo: IBD (Ulcerative Colitis / Crohn), Rheumatoid Arthritis, IgA Gammopathy / AML / MDS, alo Levamisole-Adulterated Cocaine Zazã"]
    D --> E["DEDIENƆNƆ ƑE ƉOÐO SI WOÐO BE: De dzesi si nye ‘FƆLƆ̃ ƑE NUÐEÐEŊU KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPƆKPƆ KPLE NU GBƆGBƆ O, DRY ADHERENT GAUZE AÐEKAKE O’ Dzesi ɖe Abati xa"]
    E --> F{"Afɔɖeɖe 3: Wɔ Targeted Edge Biopsy (De Violaceous Border + Subcutaneous Fat) na H&E Histopathology + Dɔlékui, Fungal & Mycobacterial Lãmetsi Dekɔnuwo"}
    F --> G{"Da Dɔléle ƒe Sesẽme, Afisi wòkeke ɖo & Dɔléle Siwo Do Ƒome Kpe Ðe Eŋu Siwo Le Eme Da"}
    G -->|Severe, Rapidly Expanding, Multilocular, or Postoperative PG| H["ƉOÐOWO ƑE ƉEÐEŊU GBÃTƆ: 1. Prednisone si woano (1 va ɖo 1.5 mg/kg/ŋkeke) ALOO Pulse IV Methylprednisolone (500 va ɖo 1,000 mg/ŋkeke x ŋkeke 3-5); ALOO 2. Cyclosporine si woano (4 va ɖo 5 mg/kg/ŋkeke - STOP GAP Dodokpɔ si Sɔ) ."]
    G -->|Coexisting Inflammatory Bowel Disease (Crohn / UC), Peristomal PG, or Steroid-Refractory Disease| I["NU GBƆGBƆ ƑE ƉEÐE: Infliximab si wodona ɖe ʋuka me (5 mg/kg le Kwasiɖa 0, 2, 6 me) alo Adalimumab + Systemic Corticosteroid Bridge"]
    G -->|Underlying Hematologic Malignancy (AML / MDS / IgA Myeloma) or Severe Sepsis Contraindicating Steroids| J["Immunoglobulin si Wodona Le Ʋuka Me ƒe Agbɔsɔsɔme Gã (IVIG 2 g/kg le ŋkeke 2-5 me) alo IL-1 ƒe Mɔxenu si Woɖo Tae (Anakinra / Canakinumab) + Da Ʋumenugbagbeviɣidɔ/Myeloma si Le Eteƒe"]
    G -->|Small (< 3 cm), Early, Localized, or Mild Peristomal Ulcer| K["Super-Potent Topical Clobetasol 0.05% Ami alo Tacrolimus 0.1% Si Wozãna Ðe Violaceous Border + Kpɔ nyuie le Intralesional Triamcinolone (40 mg/mL) + Non-Adherent Silicone Dressings"]

Dɔlélenutsiŋutete: neutrophil ahom si me dɔlékui mele o, ŋutigbalẽ ƒe vifofo, kple Pyoderma Gangrenosum ƒe dɔdamɔnu ƒe vovototo atɔ̃awo¶

Pyoderma gangrenosum nɔa neutrophilic dermatoses spectrum ƒe nuwuwu si me abi sesẽwo le (kple Sweet syndrome, subcorneal pustular dermatosis, hidradenitis suppurativa, kple erythema elevatum diutinum).

HOW MINOR TRAUMA TRIGGERS EXPLOSIVE PATHERGIC ULCERATION IN PG
=======================================================================
[Minor Cutaneous Trauma: Needle Stick, Bug Bite, Scalpel Incision]
                               |
                               v
[Keratinocyte Damage Releases DAMPs (Damage-Associated Molecular
 Patterns: ATP, HMGB1, S100 Proteins, LL-37 Cathelicidin)]
                               |
                               v
[Hyper-Reactive NLRP3 Inflammasome Activation in Dermal Macrophages]
   * Massive local surge of Interleukin-1 beta (IL-1beta), IL-1alpha,
     Tumor Necrosis Factor-alpha (TNF-alpha), IL-8 (CXCL8), IL-17,
     and Granulocyte Colony-Stimulating Factor (G-CSF).
                               |
                               v
[STERILE NEUTROPHIL AVALANCHE INTO THE DERMIS]
   * Millions of mature neutrophils flood the dermis and release
     Matrix Metalloproteinases (MMP-9, MMP-2), Neutrophil Elastase,
     Myeloperoxidase, and Neutrophil Extracellular Traps (NETs).
                               |
                               v
[LIQUEFACTIVE DERMAL COLLAGEN MELTDOWN ("Undermining")]
   * Because neutrophils dissolve the deep reticular dermis faster
     than the overlying epidermis dies, the dermal floor caves in
     beneath the skin edge -> Creates the classic BOGGY, VIOLACEOUS,
     OVERHANGING ("UNDERMINED") BORDER + Cribriform "Tissue Paper" Scar.
=======================================================================

Pyoderma Gangrenosum ƒe Dɔdamɔnu Vovototo Atɔ̃awo¶

1. Classic Ulcerative Pyoderma Gangrenosum (85% of Cases): Zi geɖe la, edona ɖe anterior pretibial lower legs (70%), akɔta, alo ƒodo dzi. Edzea egɔme abe nodule dzĩ goglo falɛfalɛ alo ʋuʋudedi si me dɔlékui mele o si ƒo xlãe kple erythematous halo si ƒoa xlãe kabakaba le titina zua abi goglo si ƒe gɔmeɖoanyi si dze abe ɖe wòle ʋeʋẽm ene kple boggy, bluish-purple (violaceous), si gblẽ liƒo si le tsia dzi. Ne ehaya le dɔlélenutsiŋutete ƒe dɔmawɔmawɔ nyuie te la, gbugbɔgadzɔ tsina tso ɖa ƒe ƒuƒoƒo siwo womeɖe o me le tɔdzisasrãwo me, si gblẽa dɔlélenutsiŋutete cribriform ("sieve-like" alo "crushed cigarette/tissue paper") atrophic scar.
2. Bullous (Atypical) Pyoderma Gangrenosum (Hematologic Malignancy Red Flag): Edzena kple acute, vevesese, gotagome concentric hemorrhagic bullae (ʋu yɔ fũ) kple blue-gray inflammatory halo, vevietɔ le mo, akɔta asiwo, kple etame nuwuwu tsɔ wu afɔwo. Critical Oncology Pearl: Dɔnɔ siwo wu 70 le alafa me siwo ŋu Bullous Pyoderma Gangrenosum le la ƒe ʋumenugbagbeviɣidɔ aɖe le wo ŋu, vevietɔ Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms, alo IgA Multiple Myeloma, kple esia zi geɖe la, ewɔa ɖeka kple bullous Sweet syndrome le dɔdamɔnu kple lãmenugbagbeviwo me.
3. Pustular Pyoderma Gangrenosum (Acute IBD Flare Marker): Edzena abe nuku siwo me vevesese, vovototo 2 va ɖo 5 milimeta sterile pustules ƒo xlãe kple erythematous halo le kekeɖenudɔa ƒe abɔwo kple etame ke si menye wo katã yi ŋgɔ yi do goglowo me o; edzɔna le Ulcerative Colitis alo Crohn Disease ƒe dzodzo sesẽ, sesẽwo me ko kloe eye wòdzudzɔna ne wotsɔ corticosteroids alo infliximab da dɔ na dɔgbo ƒe ʋuʋu.
4. Vegetative (Superficial Granulomatous) Pyoderma Gangrenosum: A blewu, si mevea ame boo o, verrucous (abe ʋuʋudedi ene), gotagome ulcerative plaque si sinus tracts si me aggressive violaceous undermined border mele o, zi geɖe la, edzɔna le akɔta le dɔnɔ siwo menye ɖoɖowɔɖi ƒe dɔléle si le ete o eye wòwɔa nu nyuie ɖe topical steroids ŋu, dapsone, alo minocycline, alo atike si nye minocycline.
5. Peristomal Pyoderma Gangrenosum (PPG): Edzɔna enumake le abdominal ileostomy alo colostomy stoma gbɔ le dɔnɔ siwo ŋu Inflammatory Bowel Disease (si nye PG dɔlélewo katã ƒe 15%), si mɔ̃ɖaŋu ƒe dɔléle si nɔa anyi didi tso Tight Stoma Appliance Wafers, adhesive stripping, alo leaking gbɔ nuɖuɖumeŋusẽ ƒe enzymewo. Esi wònye be abi goglo si le veve sem la xea mɔ na ostomy bag wafer la be wòagaxe ɖe ŋutigbalẽa ŋu o ta la, aɖuɖɔ nɔa sisim ɖe do si womeɖa o la me atraɖii, si wɔnɛ be vevesese kple mɔ̃a ƒe gbagbã ƒe tsatsam vɔ̃ɖi aɖe dona.

Domenyiŋusẽfianu ƒe Dɔléle Siwo Me Dzo Le Ðokuisi Siwo Me Pyoderma Gangrenosum (PAPA, PASH, kple PAPASH) Fia .¶

Le dɔnɔ siwo metsi o siwo ŋu pyoderma gangrenosum sesẽ, si gbugbɔna gbugbɔna kpena ɖe aklã si gblẽa nu alo hidradenitis suppurativa ŋu me la, atikewɔlawo doa monogenic autoinflammatory inflammasomopathies siwo tso tɔtrɔ siwo va le PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1) alo NCSTN . domenyiŋusẽfianu siwo naa IL-1beta wɔa dɔ wògbɔa eme: - PAPA Dɔléle: Pyogenic sterile Ƒunukpeƒetetedɔ + Pyoderma gangrenosum + cystic sesẽ Acne. - PASH Dɔléle: Pyoderma gangrenosum + Acne + Sʋuʋudedi Hidradenitis (hidradenitis suppurativa). - PAPASH / PASS Dɔlélewo: Psoriatic arthritis alo Ankylosing Spondylitis tsɔtsɔ kpe ɖe etɔ̃lia ŋu. Dɔléle siawo wɔa nu ɖe ​​IL-1 ƒe mɔxexe si woɖo taɖodzinu na (Anakinra alo Canakinumab) alo TNF-alpha mɔxenuwo (Infliximab / Adalimumab) ŋu ŋutɔ.

Vovototodedeameme le axadzi kple axadzi: Pyoderma Gangrenosum kple Necrotizing Fasciitis kple Martorell ƒe Ʋusɔgbɔdɔ ƒe Ischemic Ulcer kple Brown Recluse Spider Bite kple Levamisole Vasculopathy¶

The PARACELSUS Diagnostic Score and Mandatory Laboratory Workup for Suspected Pyoderma Gangrenosum¶

1. How to Calculate the PARACELSUS Score at the Bedside¶

Published by Jockenhovel and colleagues as a high-sensitivity diagnostic tool to distinguish pyoderma gangrenosum from venous, arterial, and infectious mimics, a total score of 10 points or higher confirms a high probability of Pyoderma Gangrenosum: - Major Criteria (3 Points Each): 1. Progressing disease (rapidly expanding ulceration developing in < 6 weeks). 2. Assessment and exclusion of relevant differential diagnoses (venous/arterial insufficiency, infection, vasculitis, calciphylaxis). 3. Reddish-violaceous (purple-blue) wound border. - Minor Criteria (2 Points Each): 4. Amelioration (rapid improvement) by immunosuppressant drugs. 5. Characteristic bizarre, polycyclic, or serpiginous ulcer shape with undermined edges. 6. Extreme pain (> 4 out of 10 on the Visual Analog Scale, often 8 to 10 out of 10). 7. Localized pathergy phenomenon (ulcer triggered at site of trauma, surgery, or biopsy). - Additional Criteria (1 Point Each): 8. Suppurative inflammation on histopathology (dense dermal neutrophilic infiltrate). 9. Undermined wound margins. 10. Systemic disease associated (IBD, rheumatoid arthritis, IgA gammopathy, hematologic malignancy).

2. Mandatory Systemic Workup in Every Newly Diagnosed Patient with Pyoderma Gangrenosum¶

Because 50 to 70 percent of patients harbor an underlying systemic disease (and because PG can be the very first clinical sign of occult Acute Myeloid Leukemia, Myelodysplastic Syndrome, IgA Multiple Myeloma, Crohn Disease, or GPA/ANCA Vasculitis), order this complete diagnostic panel upon admission: - Hematologic and Paraproteinemia Screen: Complete Blood Count (CBC) with manual peripheral blood smear (looking for myeloblasts, dysplastic neutrophils, or Auer rods), Serum Protein Electrophoresis (SPEP) with Immunofixation Electrophoresis (IFE), and Serum Free Light Chains (specifically looking for an IgA monoclonal gammopathy, the classic paraprotein associated with PG). - Gastrointestinal / Inflammatory Bowel Disease Screen: Detailed history of diarrhea, hematochezia, weight loss, or oral aphthae; Fecal Calprotectin and Ileo-colonoscopy with mucosal biopsies if any GI symptoms or unexplained iron-deficiency anemia exist. - Vasculitis, Thrombophilia, and Drug-Induced PG Screen: c-ANCA / PR3 and p-ANCA / MPO (to rule out Granulomatosis with Polyangiitis [GPA] and Levamisole-adulterated cocaine vasculopathy, which causes retiform purpura of the earlobes and PG-like leg ulcers with dual-positive MPO/HNE ANCA), Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, beta-2 glycoprotein I), Rheumatoid Factor / Anti-CCP, Hepatitis B, Hepatitis C, and HIV serologies, and Urine Toxicology for Cocaine/Levamisole. - Deep Edge Skin Biopsy Protocol (Two Specimens): Obtain a narrow elliptical incisional biopsy or 4-to-6 mm punch biopsy spanning the active erythematous-violaceous border down into subcutaneous fat: send Specimen 1 in formalin for H&E, PAS, Grocott methenamine silver (GMS), and Fite/Ziehl-Neelsen stains, and send Specimen 2 in sterile saline for aerobic, anaerobic, fungal (Blastomyces, Cryptococcus, Histoplasma, Sporothrix), and atypical mycobacterial (M. marinum, M. ulcerans, M. fortuitum) tissue cultures.

Step-by-step Hospital Treatment Protocol: Systemic Immunosuppression, Biologics, and Peristomal Care¶

1. First-Line Systemic Immunosuppression (Prednisone vs. Cyclosporine)¶

• Systemic Corticosteroids: Start Oral Prednisone or Prednisolone at 1.0 to 1.5 mg/kg/day (60 to 100 mg once daily), or for explosive postoperative or multi-ulcer disease, administer Pulse IV Methylprednisolone (500 to 1,000 mg IV daily for 3 to 5 days). Once border progression stops and the undermined overhang flattens (within 1 to 3 weeks), taper slowly over 3 to 6 months.
• Oral Cyclosporine (Calcineurin Inhibitor): Start Oral Modified Cyclosporine (Neoral) at 4 to 5 mg/kg/day divided twice daily. In the landmark STOP GAP randomized controlled trial, oral cyclosporine (4 mg/kg/day) and oral prednisolone (0.75 mg/kg/day) showed identical healing speed at 6 weeks and identical closure rates at 6 months (47%), with prednisolone carrying more serious infections and cyclosporine causing reversible renal dysfunction and hypertension. Monitor blood pressure, creatinine, potassium, and magnesium every 1 to 2 weeks.

2. Targeted Biologic and Steroid-Sparing Therapies¶

• TNF-Alpha Inhibitors (Infliximab and Adalimumab): IV Infliximab (5 mg/kg at Weeks 0, 2, and 6, then every 6 to 8 weeks) is the gold-standard biologic agent for PG, especially with Crohn Disease, Ulcerative Colitis, or Peristomal PG (screen for latent TB and Hepatitis B first). Subcutaneous Adalimumab (160 mg Week 0, 80 mg Week 2, then 40 to 80 mg weekly) is an effective subcutaneous option.
• IVIG, Steroid-Sparing Agents, and Cytokine Blockers: Give IVIG (2 g/kg over 3 to 5 days) when active malignancy or sepsis contraindicates steroids. Combine steroids or biologics with Oral Dapsone (50 to 200 mg/day after G6PD screening), Mycophenolate Mofetil, Azathioprine, or Colchicine. For refractory cases or PAPA/PASH syndromes, IL-1 antagonists (Anakinra, Canakinumab), IL-23 inhibitors (Ustekinumab), and JAK inhibitors (Upadacitinib) achieve rapid remission.

3. When Is Surgical Skin Grafting EVER Permitted in Pyoderma Gangrenosum?¶

• During Active Inflammation: NEVER. Any surgical incision, sharp debridement, or skin graft harvest (which triggers a brand-new PG ulcer at the thigh donor site) is strictly forbidden.
• During the Quiescent Healing Phase Under Full Immunosuppression: Once steroids, cyclosporine, or infliximab have completely extinguished the neutrophilic border and pain is gone, gentle slough removal, Negative Pressure Wound Therapy (NPWT), or bioengineered dermal substitutes can accelerate closure.

Nutome ƒe xexlẽdzesi siwo ku ɖe nudzɔdzɔ kpatawo ŋu kple dɔwɔƒea ƒe ɖoɖowo¶

• United States kple Canada: Ƒo ka na 911 hena ŋutigbalẽ ƒe abi siwo kaka kabakaba siwo kpe ɖe dzoxɔxɔ sesẽ, sesẽ, alo vevesese si womate ŋu ada o ŋu. Atikewɔlawo zɔna ɖe American Academy of Dermatology (AAD) kple Delphi International Consensus ƒe dɔlélewo didi kple mɔxexeɖedɔléle nu ƒe ɖoɖowo dzi.
• United Kingdom: Ƒo ka na 999 alo yi NHS ƒe Dɔwɔƒe si Kpɔa Nya Kpatawo Gbɔ. Le British Association of Dermatologists (BAD) kple UK Dermatology Clinical Trials Network (UK DCTN STOP GAP Trial) ƒe mɔfiamewo nu la, kɔdzi ŋutigbalẽŋutinunyalawo ƒe ƒuƒoƒowo dzea prednisolone (\(0.75\text{ mg/kg/day}\)) alo cyclosporine (\(4\text{ mg/kg/day}\)) si woano gɔme esime wole amekoko ƒe ŋutigbalẽ ɖeɖeɖa sesẽ dzi dem mɔxexeɖedɔa nu.
• Europa Dukɔwo ƒe Habɔbɔ: Ƒo 112 le EU dukɔwo katã me. Wɔ ɖe Europa ƒe Lãmesẽŋutinunyalawo ƒe Suku (EADV) kple Germany Lãmesẽnyawo Gbɔkpɔha (DDG) PARACELSUS Score ƒe mɔfiamewo dzi.
• Australia, New Zealand, kple Asia-Pacific: Ƒo ka na 000 le Australia, 111 le New Zealand (Australasia ƒe Lãmesẽŋutinunyalawo ƒe Kɔledzi [ACD]), 119 le Japan kple South Korea (Japantɔwo ƒe Ŋutilãŋutinunyalawo ƒe Habɔbɔ [JDA] Pyoderma Gangrenosum Mɔfiamewo, afisi Adalimumab tsɔa sedziwɔwɔ ƒe mɔɖeɖe le se nu), 995 le Singapore, alo 112 / 108 le India.

Nya siwo wobiaa amewo enuenu¶

Nukatae amekoko ƒe abi ɖeɖeɖa nana Pyoderma Gangrenosum ƒe abi la gagblẽna ɖe edzi vevie?¶

To vovo na necrotizing fasciitis (si tsoa dɔlékui siwo ɖua lã siwo wòle be woalã le amekokoxɔa me gbɔ) la, Pyoderma Gangrenosum (PG) nye dɔléle si me dɔlékuiwutikewo ƒe dɔlélenutsiŋutete kple ʋumenugbagbeviɣidɔ le si me dɔlékuiwo ŋutɔ ƒe ʋumenugbagbevi ɣiwo (neutrophils) dzea ŋutigbalẽa dzi vodadatɔe ɣesiaɣi si wòxɔ abi. Woyɔa nuwɔna sia si gbɔ eme ɖe nuveviwɔame ŋu be ŋutigbalẽ ƒe dɔléle. Ne amekola bu vodadatɔe be PG abi si me ʋuʋudedi le be enye dɔlékui ƒe dɔléle eye wòtsɔ lãgbalẽŋudɔwɔnu lã ŋutigbalẽ ƒe liƒo si le dzo dam la, ŋutigbalẽmenugbagbevi siwo gblẽ la ɖea ɣlidodo ƒe dzesiwo (interleukin-1 beta kple TNF-alpha) si yɔa neutrophil yeye miliɔn geɖe vaa nugbɔ yeye si wotso la gbɔ. Le gaƒoƒo 24 va ɖo 48 me la, neutrophil mawo ɖua collagen si le lãmesẽ me le amekokoa ƒe akpa si wowɔa dɔa le, si wɔnɛ be abi la lolona zi gbɔ zi eve alo zi gbɔ zi etɔ̃.

Aleke ɖɔktawo ate ŋu ade dzesi Postoperative Pyoderma Gangrenosum to vovo tso dɔlékui ƒe amekoko ƒe abi ƒe dɔléle le no alo ƒodo ƒe dɔwɔwɔ vɔ megbe?¶

Four clinical clues separate Postoperative Pyoderma Gangrenosum (PPG) from a bacterial wound infection: (1) Timing: PPG almost always starts 4 to 14 days after surgery as tiny sterile pustules along the incision line that suddenly merge and rip the wound open, whereas virulent Group A Strep necrotizing infections strike within 24 to 72 hours; (2) Border appearance: PPG creates a boggy, gunmetal-purple, overhanging ("undermined") skin edge; (3) Nipple sparing in breast surgery: in breast reduction or reconstruction PPG, the skin of the breast melts away while the nipple-areolar complex is uniquely spared; and (4) Antibiotic failure: PPG worsens despite broad-spectrum intravenous antibiotics and surgical debridements, yet stops expanding within 48 hours of starting high-dose corticosteroids.

Why is Pyoderma Gangrenosum called "Pyoderma" if there is no bacterial infection?¶

When dermatologists Brunsting, Goeckerman, and O'Leary first named the condition in 1930, they mistakenly believed it was caused by a runaway streptococcal or staphylococcal infection ("pyoderma" means pus in the skin) that led to tissue death ("gangrenosum"). Modern medicine later proved that the thick yellow pus covering the base of a fresh PG ulcer contains zero bacteria; it is actually a sterile soup made of millions of hyperactive white blood cells (neutrophils) that have flooded the dermis due to an overactive innate immune system. Although the name is a historical misnomer, it has remained in medical textbooks for nearly a century.

What underlying medical conditions are most commonly linked to Pyoderma Gangrenosum?¶

Between 50 and 70 percent of patients diagnosed with Pyoderma Gangrenosum have an underlying systemic illness. The four most common associations are: (1) Inflammatory Bowel Disease (Ulcerative Colitis and Crohn Disease, seen in 20% to 30% of cases); (2) Inflammatory Arthritis (Rheumatoid Arthritis and ankylosing spondylitis); (3) Hematologic cancers and blood disorders (specifically Acute Myeloid Leukemia [AML], Myelodysplastic Syndrome [MDS], and IgA Monoclonal Gammopathy, which are especially linked to the bullous variant of PG on the hands and face); and (4) Genetic autoinflammatory syndromes like PAPA and PASH syndrome.

Which works better for Pyoderma Gangrenosum: Prednisone or Cyclosporine?¶

Le UK STOP GAP ƒe dodokpɔ ɖedzesi si wowɔ le vome nu la, Prednisolone si woano (0.75 mg/kg/ŋkeke) kple Cyclosporine si woano (4 mg/kg/ŋkeke) wɔa dɔ sɔsɔe: wo ame evea siaa tɔa te abi ƒe ŋgɔyiyi le duƒuƒu ɖeka me eye wokpɔa dɔyɔyɔ blibo ƒe agbɔsɔsɔ si sɔ kloe (50% kloe haya le ɣleti 6 me). Ðɔktawo nɔa te ɖe dɔnɔa ƒe lãmesẽkuxi bubuwo dzi tiaa wo dometɔ ɖeka: Wolɔ̃a prednisone (alo IV Methylprednisolone) na dɔnɔ siwo ŋu ayikudɔ alo ʋusɔgbɔdɔ le, gake wolɔ̃a Cyclosporine na dɔnɔ siwo ŋu suklidɔ le, lolo akpa, ƒumeŋuɖui, alo tagbɔdɔléle ƒe nugbegblẽ le ame ŋu si steroid hena vɛ ŋutinya. Ne PG do ƒome kple Crohn dɔléle alo Ulcerative Colitis la, Infliximab (5 mg/kg) si wodona ɖe ʋuka me ye nye nugbagbeŋutinunya ƒe atike si wozãna le sika nu.

Dzɔtsoƒewo kple dziɖuɖumegãwo ƒe mɔfiame¶

• JAMA Dermatology Delphi Dukɔwo Dome Nubabla (Maverakis E, Ma C, Shinkai K, et al., 2018): Dzesidede Dzesiwo le Ulcerative Pyoderma Gangrenosum ŋu: Dukɔwo Dome Eŋutinunyalawo ƒe Delphi Nubabla.
• BMJ (STOP GAP Randomized Controlled Trial, Ormerod AD, Thomas KS, Craig FE, et al., UK Dermatology Clinical Trials Network): Atike Eve Siwo Wozãna Wu na Pyoderma Gangrenosum ƒe tsɔtsɔ sɔ kple wo nɔewo: STOP GAP Randomized Controlled Trial (Prednisolone vs. Ciclosporin) ƒe emetsonuwo.
• JAMA Ŋutilãŋutinunya (Jockenhovel F, et al.): PARACELSUS ƒe Dzeside: Dɔwɔnu Yeye aɖe si Wotsɔ Dia Dɔlélewo Na Pyoderma Gangrenosum.
• Britaintɔwo ƒe Lãmesẽŋutinunyalawo ƒe Habɔbɔ (BAD) kple Amerikatɔwo ƒe Lãmesẽŋutinunyalawo ƒe Suku (AAD): Dɔwɔƒe ƒe Mɔfiamewo le Neutrophilic Dermatoses, Dɔwɔwɔ vɔ megbe Pyoderma Gangrenosum ƒe Dzesidede, kple Mɔxexe Ðe Dɔléle Nu.
• Gut (Brooklyn TN, Dunnill MG, Shetty A, et al.): Infliximab na Pyoderma Gangrenosum Dada: Dodokpɔ si wowɔ le vome, si me ŋkuagbãtɔ eve le, si me wozã placebo le.

Mɔfiame siwo do ƒome kplii¶

• Calciphylaxis (calcific uremic arteriolopathy): kpe gbadzɛwo, eschars yibɔwo, kple sodium thiosulfate
• Erysipelas vs necrotizing fasciitis vs stasis dermatitis: vevesese si mesɔ gbɔ o, bullae, kple LRINEC ƒe dzesiwo ƒe vovototodedeameme
• Ahosi ameyibɔ latrodectism lãmeka ƒe sesẽ vs brown recluse loxoscelism necrotic abi triage
• Necrotizing fasciitis (lã ɖuɖu ƒe dɔlékui) kple cellulitis ƒe aflaga dzĩwo
• Xexlẽdzesi siwo woxɔna kpata le dukɔwo nu